Skip to Content

Newsletter No. 106 -- September 2008

NIH

INTEGRATION OF MOUSE MODELS INTO HUMAN CANCER RESEARCH (U01) (NCI) (RFA-CA-08-018)
Letter of intent receipt date: October 14, 2008
Application Receipt Date(s): November 14, 2008
This FOA extends the NCI-Mouse Models of Human Cancers Consortium (NCI-MMHCC) for a third project period. The previous periods resulted in generation, validation, and utilization of many novel mouse cancer models. Having successfully attained the original specific program goals, the NCI-MMHCC is poised to enter the next stage that stresses the use of biologically relevant mouse models as effective tools for human research. The overall objective of the NCI-MMHCC is integration of mouse models into basic, translational, epidemiological, and clinical cancer research.
URL: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-08-018.html

ETIOLOGY, PREVENTION, AND TREATMENT OF HEPATOCELLULAR CARCINOMA (R01: PA-08-243) (R21: PA-08-244) (P01: PAR-08-245) (NCI, NIAAA, NIDDK)
Application Receipt Date(s) for R01, R21: Multiple dates, see announcement. Application Receipt Date for P01: Multiple dates, starting October 20, 2008 (see announcement for Letter of Intent receipt dates).
With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI), invites grant applications that: (a) address the etiology and etiologic mechanisms of hepatocellular carcinoma (HCC); (b) propose development of animal models for HCC; (c) propose novel approaches to prevent HCC malignancy; (d) propose therapeutic or diagnostic tools for reliable prognostic indicators for HCC; and/or (e) develop therapeutic approaches to minimize morbidity and mortality associated with HCC in humans. The primary focus of the proposed projects must be on the basic biology, prevention, and/or treatment of liver cancer. The specific research areas of interest include a number of imaging topics.
URL for R01: http://grants.nih.gov/grants/guide/pa-files/PA-08-243.html
URL for R21: http://grants.nih.gov/grants/guide/pa-files/PA-08-244.html
URL for P01: http://grants.nih.gov/grants/guide/pa-files/PAR-08-245.html

EXCEPTIONAL, UNCONVENTIONAL RESEARCH ENABLING KNOWLEDGE ACCELERATION (EUREKA) (R01)
(RFA-GM-09-008) (NCI AND MULTIPLE INSTITUTES)

Letter of intent due: September 29, 2008
Application Receipt Date: October 28, 2008
NCI: The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. NCI welcomes EUREKA applications for all program areas supported by the Institute.
URL: http://grants.nih.gov/grants/guide/rfa-files/RFA-GM-09-008.html

ANCILLARY STUDIES IN CLINICAL TRIALS (R01) (NHLBI) (RFA-HL-09-001)
Letters of Intent Receipt Date(s): December 30, 2008, April 29, 2009, August 31, 2009
Application Receipt Date(s): January 30, 2009, May 29, 2009, September 30, 2009
The purpose of this Funding Opportunity Announcement (FOA) is to solicit research grant applications to conduct time-sensitive ancillary studies related to heart, lung, and blood diseases and sleep disorders in conjunction with ongoing NIH- or non-NIH-supported clinical trials.
The following are examples of research that might be proposed under this program. These are only examples and are not meant to be inclusive. Applicants can propose other ancillary studies consistent with the goals of this program: Cardiovascular: Mechanisms underlying cardiovascular abnormalities and sequelae including hypertension, heart failure, sudden death, sleep disordered breathing; studies of cardiac energetics (MRI, PET) before and after control of metabolic abnormalities; imaging studies to elucidate disease progression or mechanism of action of the intervention; identification and validation of biomarkers of cardiovascular diseases.
URL: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-09-001.html

NATIONAL COOPERATIVE DRUG DISCOVERY AND DEVELOPMENT GROUPS (NCDDDG) FOR THE TREATMENT OF MENTAL DISORDERS, DRUG OR ALCOHOL ADDICTION (U01/U19)(PAR-08-238) (NIMH, NIAAA, NIDA)
Letters of Intent Receipt Date(s): September 3, 2008; January 24, 2009; August 17, 2009
Application Receipt/Submission Date(s): October 3, 2008; February 24, 2009; September 17, 2009
Each NCDDDG program should consist of a multi-disciplinary team of scientists with appropriate expertise to further the development and evaluation of novel compounds. Scientists from both academia and pharmaceutical industry are encouraged to participate within an NCDDDG; scientists from foreign institutions and NIH Intramural laboratories may participate in some aspects, as noted in other sections of this funding opportunity. It is anticipated that the interaction of academic and non-profit research institutions with industry and NIH via the NCDDDG model will: 1) accelerate the discovery and development of new therapeutics for mental disorders, drug or alcohol addiction; 2) increase the availability of pharmacologic research tools (including imaging agents) for basic and clinical research; 3) facilitate the development and validation of models to evaluate novel therapeutics for mental disorders; 4) increase the availability of new IND-ready compounds suitable for testing in humans; and 5) facilitate the development and validation of new clinical measures or biomarkers suitable for use in human proof of concept trials of novel therapeutics for mental disorders or alcohol addiction.
URL: http://grants.nih.gov/grants/guide/pa-files/PAR-08-238.html

COMPREHENSIVE ALCOHOL RESEARCH CENTER ON HIV/AIDS (P60) (RFA-AA-09-002) (NIAAA)
Letter of intent due: April 1, 2009
Application Receipt Date: May 01, 2009
Through this FOA, NIAAA seeks to encourage basic research that can be translated into interventions in order to reduce infection and transmission of HIV. Among the specific research objectives is developing research on combining neuroimaging and neuropsychological assessment to determine the relationship between medication adherence, biomarkers of HIV infection, and the decline in brain and cognitive function in HIV-infected heavy drinkers and identifying markers for neuropsychological functioning that will be predictive of treatment efficacy.
URL: http://grants.nih.gov/grants/guide/rfa-files/RFA-AA-09-002.html

TRANSLATIONAL RESEARCH IN FEMALE PELVIC FLOOR DISORDERS (NICHD) (R03: RFA-HD-08-009)
Application Receipt Date: October 30, 2008
This FOA solicits applications from institutions/organizations that propose to enhance collaborative research among basic scientists and clinician researchers in female pelvic floor disorders. …Examples of research topics include, but are not limited to, those listed below: Develop new avenues for diagnostic testing with improved test performance; this could include imaging modalities.
URL: http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-08-009.html

TRANSLATIONAL RESEARCH AT THE AGING/CANCER INTERFACE (NIA) (TRACI) (R01: PA-08-230) (R21: PA-08-231)
Application Receipt Date(s): Multiple dates, see announcement.
This FOA encourages research grant applications from institutions/organizations that propose translational research in the overlapping areas of human aging and cancer, linking basic and clinical research relevant to the care of older cancer patients through both "bench to bedside" and "bedside to bench" approaches. Examples of research areas include, but are not limited to: Translating new bioengineering technologies (novel imaging techniques, methods for non-invasive evaluation of tissue characteristics, etc.) to address age-related problems in risk assessment, prevention, and early detection of cancer in older persons.
URL for R01: http://grants.nih.gov/grants/guide/pa-files/PA-08-230.html
URL for R21: http://grants.nih.gov/grants/guide/pa-files/PA-08-231.html

CHRONIC FATIGUE SYNDROME: PATHOPHYSIOLOGY AND TREATMENT (R01) (MULTIPLE INSTITUTES)(PA-08-246) (R21: PA-08-247)
Application Receipt/Submission Date(s): Multiple dates, see announcement.
This FOA encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology, and treatment of chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME/CFS) in diverse groups and across the lifespan. …Applications within, but not limited to the following, may propose to explore the role of neuroimaging modalities in the diagnosis, treatment and progression of CFS.
URL for R01: http://grants.nih.gov/grants/guide/pa-files/PA-08-246.html
URL for R21: http://grants.nih.gov/grants/guide/pa-files/PA-08-247.html

SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM CONTRACT SOLICITATION (PHS 2009-1) NOW AVAILABLE (NOT-OD-08-094)
Proposals Due: November 3, 2008
The purpose of this notice is to (1) announce the issuance of the Solicitation of the National Institutes of Health and the Centers for Disease Control and Prevention for Small Business Innovation Research Contract Proposals (PHS 2009-1) with a receipt date of November 3, 2008; and (2) inform the public about the opportunities that the SBIR program offers to small business concerns as well as to scientists at research institutions.
URL: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-094.html

NIH OFFERS SBIR NICHE ASSESSMENT PROGRAM TO PHASE I AWARDEES (NOT-OD-08-100)
Seventy-five (75) slots are available and will be filled on a "first come, first served" basis. Only NIH FY 08 and FY 09 SBIR Phase I awardees (not STTR) are eligible to participate. For those with multiple awards, only one project per company will be accepted for Group A (see below), but others will be considered if space is available in Group B. Group A will include 50 slots and Group B 25. You may sign up at any time for either but it is suggested that you carefully consider your group selection in relation to when you plan to submit your Phase II application as the Technology Niche Analysis™ report may be helpful in the preparation of the commercialization plan that is required in an SBIR Phase II application.
URL: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-100.html

CIP Announcements

CIP DCIDE PROGRAM
The Cancer Imaging Program of the NCI requests submissions for its Development of Clinical Imaging Drugs and Enhancers (DCIDE) initiative. The goal is the rapid movement of promising, novel cancer imaging enhancers or molecular probes from the laboratory to proof of principle clinical trials. See the web site for details.
URL: http://imaging.cancer.gov/programsandresources/specializedinitiatives/dcide

GUEST AUTHOR OPPORTUNITIES IN THE NIH MICAD DATABASE
The Molecular Imaging and Contrast Agent Database (MICAD) program has been developed as a key component of the NIH Molecular Imaging Roadmap to provide freely accessible online scientific information on in vivo molecular imaging and contrast agents. To accelerate expansion of the database to include all published agents, the MICAD program has implemented a procedure for members of the imaging community to write and submit entries (chapters) as guest authors to the database. All members of the imaging community are encouraged to consider this guest author opportunities. For further information, please contact the MICAD staff at micad@ncbi.nlm.nih.gov. Individual guest authors will be provide with detailed instructions, style guidelines, and a chapter template. The name of the contributing author(s) will be acknowledged and included in the MICAD online publication.
URL: http://micad.nih.gov
URL: http://bookshelf.ncbi.nlm.nih.gov/books/bookres.fcgi/micad/infoguest.html

Notices

Notice of Deadline Extension for Request for Information Soliciting Input on Emerging Capabilities for Non-Invasive Imaging of Brain Structure and Function (Neuroscience Blueprint) (Multiple institutes) (NOT-AG-08-007, re NOT-AG-08-005)
Date changed to September 2, 2008
URL: http://grants.nih.gov/grants/guide/notice-files/NOT-AG-08-007.html

Change in Allowable Requested Budget Levels of Renewal (Type 2) R01, U01, and P01 Applications for the National Cancer Institute (NOT-CA-08-026)
The direct cost budget request for the first year cannot generally exceed an increase of 10% over the direct cost budget awarded for the last year of the prior project period (i.e., the last Type 5 award).
URL: http://grants.nih.gov/grants/guide/notice-files/NOT-CA-08-026.html

NIH Announces the Posting of a Web-based Tutorial on Financial Conflict of Interest Requirements for All NIH-Supported Institutions (NOT-OD-08-106)
Tutorial may be accessed at http://grants.nih.gov/grants/policy/coi/index.htm
URL: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-106.html

Meetings

World Molecular Imaging Congress
Sponsored by the Society for Molecular Imaging (SMI), the Academy of Molecular Imaging (AMI), the European Society for Molecular Imaging (ESMI) and the Federation of Asian Societies for Molecular Imaging (FASMI)
Cancer Imaging Program Booth 711
September 10-13, 2008, Nice, France
URL: http://www.wmicmeeting.org/dev/

ISMRM Workshop on Frontiers of Magnetic Resonance: From Tumor Cell to Cancer Patient,
September 13-16, 2008, Nice, France
URL: http://www.ismrm.org/workshops/Cancer_08/index.htm

ACRIN Fall Meeting,
October 2-5, 2008, Ritz-Carleton Pentagon City, Arlington, VA
URL: https://registrations.acr.org/acrin/

First International MR Focused Ultrasound Surgery Symposium,
October 6-7, 2008, Washington, DC
URL: http://www.fusfoundation.org/symposium/

Seventh International Conference on the Ultrasonic Measurement and Imaging of Tissue Elasticity,
October 27-30, 2008, The Lakeway Resort and Spa, Lake Travis, Austin, TX
URL: http://www.uth.tmc.edu/schools/med/rad/elasto/conference/

4th Annual Small Animal Imaging Workshop,
November 5-8, 2008, Clark Auditorium, Stanford University
URL: http://radiologycme.stanford.edu/2008smallanimal/

5th Annual Memphis BioImaging Conference,
November 6-7, 2008, Fogelman Executive Conference Center, Memphis, TN
URL: http://www.membis.org/

2008 RSNA Meeting,
November 30 - December 5, 2008, McCormick Place, Chicago, Illinois
URL: http://rsna2008.rsna.org/#


If you wish to remain on the list, no action is necessary. If you wish to be added to the list, please contact Dr Barbara Croft by return e-mail (bc129b@nih.gov). Please include your complete mailing address, title, phone and fax numbers.

Cancer Imaging Program,
Division of Cancer Treatment and Diagnosis,
NCI 6130 Executive Boulevard - MSC-7412
Bethesda, MD 20892-7412
Tel: 301 496 9531
Fax: 301 480 3507